Customers are innovators and specialty pharmaceutical companies in regulated markets; US revenue for the half-year was ₹2,161 crore, up 37%, Europe and other regulated markets revenue was ₹411 crore, up 23%, rest-of-world revenue was ₹204 crore and India revenue was ₹38.7 crore.
Recent events
| Catalyst | Timing | Size | What has to go right |
|---|---|---|---|
| US FDA inspection of the additional bag manufacturing line, after which products from the line could be commercialized and the capacity constraint eased. | — | — | The inspection has to conclude so that the line can be used for commercial supply. |
| NUPCO tender results from Saudi Arabia, which management says are delayed. | — | — | The tender has to be announced; management says it has participated with about 13 products and is confident of winning products in that segment. |
On operating margin, the company's 27.3% is above the peer median of 13.5% for the 241 companies in the peer group with a value, ranking 37 of 241.
| Metric | GLAND | Peer median | Rank |
|---|---|---|---|
| Operating margin | 27.3% | 13.5% | 37 of 241 |
| Return on capital employed | 15.1% | 12.5% | 97 of 242 |
| Return on equity | 10.7% | 10.5% | 115 of 236 |
Compared with 248 companies in Pharmaceuticals & Biotechnology (medians; data as of 15 Nov 2026). Rank 1 is best, except price multiples, where 1 is lowest.
| Sep 2026 | Latest | vs year ago | vs prior quarter |
|---|---|---|---|
| Revenue | ₹1,834 cr | 23.3% | 1.9% |
| EBITDA | ₹484 cr | 54.1% | -1.0% |
| Profit after tax | ₹291 cr | 58.2% | -8.2% |
Market capitalisation ₹55,016 cr · trailing 12-month profit after tax ₹1,236 cr · price-to-earnings 44.5x
| Assumed yearly return to shareholders | Profit needed at the end | Implied yearly profit growth |
|---|---|---|
| 12.0% | ₹1,737 cr | 12.0% |
A calculation, not a forecast: 3-year horizon, the multiple unchanged and a constant share count.
| Holder | Sep 2026 | Jun 2026 | Change |
|---|---|---|---|
| Promoters | 45.8% | 51.8% | −6.0 pp |
| Foreign institutions | 10.4% | 8.7% | +1.6 pp |
| Domestic institutions | 33.2% | 30.4% | +2.8 pp |
Facts from company filings, exchange data and company documents, with calculations shown. Educational information; not investment advice.
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Create a free Finmagine account to access Finmagine™ Scorecard.
See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.
Upgrade to Finmagine Premium to unlock Ask AI.
Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.
Upgrade to Finmagine Premium to unlock Peer Comparison.
Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.
Upgrade to Finmagine Premium to unlock Documents.
Access concall transcripts, annual reports, credit ratings, and investor presentations.
Upgrade to Finmagine Premium to unlock Catalyst Timeline.
Every result, order win, insider trade, SAST trigger, pledge change, concall, and corporate action for this company — in one chronological lane.
Upgrade to Finmagine Premium to unlock Forensic Report.
A filings-based disclosure review of this company's most recent Annual Report — Accounting Quality Signals, Related Party Disclosures, Auditor Signals, and Governance Watchpoints, generated with your own AI key.
Upgrade to Finmagine Premium to unlock Full Report.
Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.
This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.
A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.
Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.
No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.
Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.
Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.
Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.
Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.
Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.